Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01857193
Title	Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Recruitment	Completed
Gender	female
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Novartis Pharmaceuticals
Indications	progesterone-receptor positive breast cancer estrogen-receptor positive breast cancer
Therapies	Everolimus + Exemestane + Ribociclib Exemestane + Ribociclib
Age Groups:	adult \| senior
Covered Countries	USA \| FRA \| ESP \| BEL

Filter rows:

Showing 1 to 13 of 13 entries

Facility	City	State	Zip	Country	Details
Highlands Oncology Group	Fayetteville	Arkansas	72703	United States	Details
Karmanos Cancer Institute Dept of Onc	Detroit	Michigan	48201	United States	Details
Massachusetts General Hospital Onc Dept	Boston	Massachusetts	02114	United States	Details
Memorial Sloan Kettering Oncology Dept.	New York	New York	10017	United States	Details
Northwest Medical Specialties	Tacoma	Washington	98405	United States	Details
Novartis Investigative Site	Wilrijk		2610	Belgium	Details
Novartis Investigative Site	Saint Herblain cedex		44805	France	Details
Novartis Investigative Site	Hong Kong			Hong Kong	Details
Novartis Investigative Site	Barcelona	Catalunya	08035	Spain	Details
Novartis Investigative Site	Hospitalet de LLobregat	Catalunya	08907	Spain	Details
Oregon Health and Science University SC-5	Portland	Oregon	97239	United States	Details
Sylvester Comprehensive Cancer Center Main Center	Miami	Florida	33136	United States	Details
University of Texas MD Anderson Cancer Center Onc Dept	Houston	Texas	77030	United States	Details

Showing 1 to 13 of 13 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field